Sector News

Big Pharma vs. ‘growth pharma’? Let Actavis chief detail the differences

January 14, 2015
Life sciences
Actavis may be a big pharma now that it’s joining hands with Allergan, but it’s not a Big Pharma, CEO Brent Saunders insists. The merger partners are taking the term “growth pharma” and running with it as they set out to differentiate themselves from the industry’s slow-growing stalwarts.
 
As opposed to the peers Actavis will join on the list of top-10 drugmakers by worldwide revenue, the Dublin drugmaker envisions compound annual growth of 10% for its branded drug business, its chief exec said Tuesday at the JP Morgan Healthcare Conference. It’ll hit that mark by exemplifying 5 key characteristics it’s identified to define “growth pharma,” including highly efficient SG&A spending, sustainable commercial franchises with extended IP protection, and a strong global commercial footprint, Saunders said. They’re not unfamiliar goals in Big Pharma, of course, but execution is everything.
 
And while Actavis may not want to follow in Big Pharma’s footsteps where growth is concerned, it’s certainly singing a familiar tune when it comes to core therapeutic areas. Over the past few years, drug giants have been slimming down to make sure they can prioritize their key areas and focus on what they do well–something Actavis says it’ll do with gastrointestinal treatments, eye care, women’s health, CNS drugs, and aesthetic dermatology.
 
If it can be No. 1 or No. 2 in each of those areas, Actavis can create an “ecosystem where everybody wants to bring us their ideas, their innovations, so that we can continually source new things,” Saunders said. And he’s convinced Actavis can draw in those forward-thinkers. “We’re easy to work with. We’re action-oriented, we make fast decisions, we’re thorough. But we also make polite ‘no’s’ very quickly,” he said–something entrepreneurs, VCs and academics respect. Big Pharma isn’t exactly known for the same thing.
 
In the meantime, the company is still working to fold in Allergan’s operations–an integration Saunders says is going exceptionally well. “This is probably going along the best of any I’ve been involved in,” he noted–which is saying a lot considering the jump he’s made from Bausch + Lomb to Forest Labs to Actavis in the past two years alone. Of course, that’s “not to say we don’t have our issues or challenges,” Saunders said. “But we’re working through everything and making very good progress.”
 
By Carly Helfand
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”